First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease…
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete…
NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced…
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a…
Data Presented at ESMO Immuno-Oncology CongressSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in Current OCU400 Clinical Trial MALVERN,…
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and…
Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner…
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused…
CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a…